ProQR Therapeutics N.V (PRQR) Net Income towards Common Stockholders: 2021-2025
Historic Net Income towards Common Stockholders for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -$12.9 million.
- ProQR Therapeutics N.V's Net Income towards Common Stockholders fell 38.37% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.3 million, marking a year-over-year decrease of 86.78%. This contributed to the annual value of -$29.7 million for FY2024, which is 2.46% up from last year.
- As of Q3 2025, ProQR Therapeutics N.V's Net Income towards Common Stockholders stood at -$12.9 million, which was up 11.43% from -$14.6 million recorded in Q2 2025.
- In the past 5 years, ProQR Therapeutics N.V's Net Income towards Common Stockholders ranged from a high of -$2.9 million in Q2 2024 and a low of -$23.5 million during Q3 2022.
- In the last 3 years, ProQR Therapeutics N.V's Net Income towards Common Stockholders had a median value of -$9.3 million in 2024 and averaged -$9.0 million.
- As far as peak fluctuations go, ProQR Therapeutics N.V's Net Income towards Common Stockholders skyrocketed by 72.01% in 2023, and later slumped by 402.18% in 2025.
- Over the past 5 years, ProQR Therapeutics N.V's Net Income towards Common Stockholders (Quarterly) stood at -$20.8 million in 2021, then skyrocketed by 34.92% to -$13.6 million in 2022, then skyrocketed by 60.85% to -$5.3 million in 2023, then slumped by 85.19% to -$9.8 million in 2024, then slumped by 38.37% to -$12.9 million in 2025.
- Its last three reported values are -$12.9 million in Q3 2025, -$14.6 million for Q2 2025, and -$11.0 million during Q1 2025.